Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury.

OBJECTIVES This study evaluated intracardiac angiotensin-converting enzyme inhibition as an adjuvant to cardioplegia and examined its effects on hemodynamic, metabolic, and ultrastructural postischemic outcomes. METHODS The experiments were performed with an isolated, erythrocyte-perfused, rabbit working-heart model. The hearts excised from 29 adult New Zealand White rabbits (2950 +/- 200 g) were randomly assigned to four groups. Two groups received quinaprilat (1 microg/mL), initiated either with cardioplegia (n = 7) or during reperfusion (n = 7). The third group received l-arginine (2 mmol/L) initiated with cardioplegia (n = 7). Eight hearts served as a control group. Forty minutes of preischemic perfusion were followed by 60 minutes of hypothermic arrest and 40 minutes of reperfusion. RESULTS All treatments substantially improved postischemic recovery of external heart work (62% +/- 6%, 69% +/- 3%, and 64% +/- 5% in quinaprilat during cardioplegia, quinaprilat during reperfusion, and l-arginine groups, respectively, vs 35% +/- 5% in control group, P <.001) with similarly increased external stroke work and cardiac output. When administered during ischemia, quinaprilat significantly improved recovery of coronary flow (70% +/- 8%, P =.028 vs quinaprilat during reperfusion [49% +/- 5%] and P =.023 vs control [48% +/- 6%]). l-Arginine (55% +/- 7%) showed no significant effect. Postischemic myocardial oxygen consumption remained low in treatment groups (4.6 +/- 1.2 mL. min(-1). 100 g(-1), 6.0 +/- 2.2 mL. min(-1). 100 g(-1), and 4.7 +/- 1.6 mL. min(-1). 100 g(-1) in quinaprilat during cardioplegia, quinaprilat during reperfusion, and l-arginine groups, respectively, vs 4.2 +/- 0.8 mL. min(-1). 100 g(-1) in control group), even though cardiac work was markedly increased. High-energy phosphates, which were consistently elevated in all treatment groups, showed a significant increase in adenosine triphosphate with quinaprilat during ischemia (2.24 +/- 0.14 micromol/g vs 1.81 +/- 0.12 micromol/g in control group, P =.040). Ultrastructural grading of mitochondrial damage revealed best preservation with quinaprilat during ischemia (100% [no damage], P =.001 vs control). CONCLUSION These experimental findings have clinical relevance regarding prevention of postoperative myocardial stunning and low coronary reflow in patients undergoing heart surgery.

[1]  H. Schima,et al.  The erythrocyte-perfused "working heart" model: hemodynamic and metabolic performance in comparison to crystalloid perfused hearts. , 1999, Journal of pharmacological and toxicological methods.

[2]  H. Drexler,et al.  Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[3]  J. Keaney,et al.  Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization. , 1998, The Annals of thoracic surgery.

[4]  M. Carrier,et al.  Can L-arginine improve myocardial protection during cardioplegic arrest? Results of a phase I pilot study. , 1998, The Annals of thoracic surgery.

[5]  M. Amrani,et al.  The effect of L-arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. , 1997, Circulation.

[6]  G. He,et al.  Superiority of hyperpolarizing to depolarizing cardioplegia in protection of coronary endothelial function. , 1997, The Journal of thoracic and cardiovascular surgery.

[7]  A. Danser,et al.  Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. , 1997, Hypertension.

[8]  J. Gurevitch,et al.  Captopril in cardioplegia and reperfusion: protective effects on the ischemic heart. , 1997, The Annals of thoracic surgery.

[9]  G. Buckberg,et al.  Endothelial stunning and myocyte recovery after reperfusion of jeopardized muscle: a role of L-arginine blood cardioplegia. , 1997, The Journal of thoracic and cardiovascular surgery.

[10]  X. Xu,et al.  ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. , 1997, Circulation.

[11]  M. G. St. John Sutton,et al.  Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). , 1996, Journal of the American College of Cardiology.

[12]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[13]  S. Cohen,et al.  Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. , 1996, Journal of cardiovascular pharmacology.

[14]  F. Sellke,et al.  Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. , 1996, Circulation.

[15]  N. Maulik,et al.  Nitric oxide signaling in ischemic heart. , 1995, Cardiovascular research.

[16]  A. Cordell Milestones in the development of cardioplegia. , 1995, The Annals of thoracic surgery.

[17]  M. Hori,et al.  Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. , 1995, Circulation.

[18]  J. Hammon,et al.  Blood cardioplegia enhanced with nitric oxide donor SPM-5185 counteracts postischemic endothelial and ventricular dysfunction. , 1995, The Journal of thoracic and cardiovascular surgery.

[19]  P. Buser,et al.  Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin. , 1995, Cardiovascular research.

[20]  H. Lutz,et al.  Microvascular dysfunction after myocardial ischemia. , 1995, The Journal of thoracic and cardiovascular surgery.

[21]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[22]  B. F. Becker,et al.  Nitric Oxide Accounts for Postischemic Cardioprotection Resulting from Angiotensin‐Converting Enzyme Inhibition: Indirect Evidence for a Radical Scavenger Effect in Isolated Guinea Pig Heart , 1995, Journal of cardiovascular pharmacology.

[23]  A. G. Scicli,et al.  Coronary flow reserve after ischemia and reperfusion of the isolated heart. Divergent results with crystalloid versus blood perfusion. , 1995, The Journal of thoracic and cardiovascular surgery.

[24]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[25]  T. Ehring,et al.  Attenuation of Myocardial Stunning by the ACE Inhibitor Ramiprilat Through a Signal Cascade of Bradykinin and Prostaglandins but not Nitric Oxide , 1994, Handbook of Experimental Pharmacology.

[26]  G. Plosker,et al.  Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. , 1994, Drugs.

[27]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[28]  E. Wolner,et al.  New developments in the isolated working heart: a comparison of neonatal, immature, and adult rabbits after sixty minutes of ischemia in respect to hemodynamic and biochemical parameters. , 1993, Journal of pharmacological and toxicological methods.

[29]  W. Linz,et al.  ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. , 1992, Journal of molecular and cellular cardiology.

[30]  S. Hallström,et al.  Simultaneous determination of myocardial nucleotides, nucleosides, purine bases and creatine phosphate by ion-pair high-performance liquid chromatography. , 1992, Journal of chromatography.

[31]  P. Menasché,et al.  Pretreatment with Captopril Improves Myocardial Recovery After Cardioplegic Arrest , 1992, Journal of cardiovascular pharmacology.

[32]  A. Peitzman,et al.  Nitrogen oxide levels in patients after trauma and during sepsis. , 1991, Annals of surgery.

[33]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.

[34]  W. Schaper,et al.  Ultrastructural, functional, and biochemical criteria for estimation of reversibility of ischemic injury: a study on the effects of global ischemia on the isolated dog heart. , 1979, Journal of molecular and cellular cardiology.

[35]  R. Ferrari,et al.  Effect of angiotensin converting enzyme inhibition with quinaprilat on the ischaemic and reperfused myocardium. , 1994, Journal of molecular and cellular cardiology.

[36]  F. Sellke,et al.  Impaired endothelium-dependent coronary microvascular relaxation after cold potassium cardioplegia and reperfusion. , 1993, The Journal of thoracic and cardiovascular surgery.

[37]  J. Tomaszewski,et al.  Renin and angiotensin. , 1968, Lancet.